Atreca

San Carlos, United States Founded: 2010 • Age: 16 yrs
Antibody therapeutics for anti-cancer immune responses are developed.
Request Access

About Atreca

Atreca is a company based in San Carlos (United States) founded in 2010.. Atreca has raised $224.4 million across 9 funding rounds from investors including Gates Foundation, GSK and Tekla Capital Management. The company has 134 employees as of December 31, 2021. Atreca operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.

  • Headquarter San Carlos, United States
  • Employees 134 as on 31 Dec, 2021
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Atreca, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $224.4 M (USD)

    in 9 rounds

  • Latest Funding Round
    $125 M (USD), Series C

    Sep 12, 2018

  • Investors
  • Employee Count
    134

    as on Dec 31, 2021

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Atreca
Headcount 50-200
Employee Profiles 9
Board Members and Advisors 12
Employee Profiles
People
Tito A. Serafini
Chief Strategy Officer & Founder
People
Courtney Phillips
General Counsel & Corporate Secretary
People
Stephen Gould
Chief Scientific Officer
People
Xiaomu Chen
Scientist

Unlock access to complete

Board Members and Advisors
people
Kristine M. Ball
Director

Unlock access to complete

Funding Insights of Atreca

Atreca has successfully raised a total of $224.4M across 9 strategic funding rounds. The most recent funding activity was a Series C round of $125 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series C — $125.0M
  • First Round

    (11 Nov 2011)

  • Investors Count 10
Date Amount Transaction Name Valuation Lead Investors Investors
Sep, 2018 Amount Series C - Atreca Valuation Aisling Capital , EcoR1
Aug, 2017 Amount Series B - Atreca Valuation Wellington
Oct, 2015 Amount Series A - Atreca Valuation Gates Foundation , GSK
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Atreca

Atreca has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, GSK and Tekla Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
Venture capital funding is provided by Samsara BioCapital in California.
Founded Year Domain Location
Biotech startups are funded by this venture capital firm.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Atreca

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Atreca

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Atreca Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Atreca

Atreca operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Novel biopharmaceutical medicines are developed for unmet medical needs.
domain founded_year HQ Location
Targeted and immune-oncology drugs for cancer treatment are developed.
domain founded_year HQ Location
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
domain founded_year HQ Location
Small molecules are developed for cancer and skin disease treatments.
domain founded_year HQ Location
Cancer therapies are developed using selective pathway inhibitors.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Atreca

Frequently Asked Questions about Atreca

When was Atreca founded?

Atreca was founded in 2010 and raised its 1st funding round 1 year after it was founded.

Where is Atreca located?

Atreca is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.

Is Atreca a funded company?

Atreca is a funded company, having raised a total of $224.4M across 9 funding rounds to date. The company's 1st funding round was a Series A of $57.26M, raised on Nov 11, 2011.

How many employees does Atreca have?

As of Dec 31, 2021, the latest employee count at Atreca is 134.

What does Atreca do?

Developer of antibody therapeutics for human anti-cancer immune responses. Atrecas proprietary Immune Repertoire Capture technology profiles a patients immune response at the single-cell level, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. Its technology can be used for the discovery and development of antibody-based therapeutics and for identifying the critical targets of effective immune responses. It is applying its technology to generate and develop a novel class of cancer immunotherapies including therapeutics that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.

Who are the top competitors of Atreca?

Atreca's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.

Who are Atreca's investors?

Atreca has 10 investors. Key investors include Gates Foundation, GSK, Tekla Capital Management, Wellington, and Aisling Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available